{"nctId":"NCT00572572","briefTitle":"Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors","startDateStruct":{"date":"2007-12"},"conditions":["Germ Cell Tumors"],"count":69,"armGroups":[{"label":"Arm A: Aprepitant, Then Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Aprepitant","Drug: Placebo"]},{"label":"Arm B: Placebo, Then Aprepitant","type":"EXPERIMENTAL","interventionNames":["Drug: Aprepitant","Drug: Placebo"]}],"interventions":[{"name":"Aprepitant","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic, serologic or clinical evidence of germ cell tumor.\n* Patients scheduled to receive a 5 day fractionated cisplatin-based combination chemotherapy on permitted regimens\n* Prior chemotherapy is allowed. Patients will be stratified based on previous treatment.\n* Male patients 15 years of age or older at time of registration.\n* Patient will provide written informed consent and authorization to release personal health information.\n\nExclusion Criteria:\n\n* No known history of anticipatory nausea or vomiting.\n* No use of another antiemetic agent within 72 hours prior to beginning chemotherapy.\n* No known central nervous system (CNS) metastasis.\n* No known hypersensitivity to any component of study regimen.\n* No concurrent participation in a clinical trial which involves another investigational agent.\n* No use of warfarin while on study.\n* No use of agents expected to induce the metabolism of aprepitant which include: Rifampin, Rifabutin, Phenytoin, Carbamazepine, and barbiturates.\n* No use of agents which may impair metabolism of aprepitant which include: Cisapride, macrolide antibiotics (Erythromycin, Clarithromycin, Azithromycin), azole antifungal agents (Ketoconazole, Itraconazole, Voriconazole, Fluconazole), Amifostine, Nelfinavir and Ritonavir.","healthyVolunteers":false,"sex":"MALE","minimumAge":"15 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response.","description":"Participants were followed for chemotherapy induced nausea and vomiting (CINV) through day 8 of cycle 2. Complete response is defined as no emetic episodes and no use of rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With no Emesis During the Acute CINV Time Period (Cycle Days 1-5)","description":"Proportion of patients with no emesis regardless of use of rescue medication during cycle days 1-5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With no Emesis During the Delayed CINV Time Period (Cycle Days 6-8)","description":"Proportion of patients with no emesis regardless of use of rescue medication during cycle days 6-8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Visual Analouge (VAS) 100mm Scale Score","description":"The Visual Analouge (VAS) 100mm Scale Score for Chemotherapy Induced Nausea and Vomiting (CINV). Participants were asked to mark a linear scale 100mm in length representing their level of nausea with 0mm indicating no nausea and 100mm indicating severe nausea. The mean VAS scores for days 1-8 combined, by treatment (Aprepitant vs. Placebo) were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"18.7"},{"groupId":"OG001","value":"27.1","spread":"22.1"}]}]}]},{"type":"SECONDARY","title":"MD Anderson Symptom Inventory Score","description":"The MD Anderson Symptom Inventory (MDASI) is a brief measure of the severity and impact of cancer-related symptoms. Thirteen core items measure the severity of symptoms and six additional items measure the impact of symptoms. All items are rated on a scale from 0 (not present or did not interfere) to 10 (maximal severity or interference). The mean value of the total nineteen items ranges from 0 to 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"3.4"},{"groupId":"OG001","value":"2.9","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Preferred Treatment Cycle","description":"Participants were asked which treatment cycles was preferable - aprepitant or placebo cycle.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":35},"commonTop":["NAUSEA","FATIGUE (ASTHENIA, LETHARGY, MALAISE)","HAIR LOSS/ALOPECIA (SCALP OR BODY)","HEARTBURN/DYSPEPSIA","INSOMNIA"]}}}